The KBA helps address fundamental strategic issues critical to the success of emerging Kansas bioscience enterprises.
The KBA hosts and presents bioscience and related industry meetings, conferences, and networking events.
Since the Kansas Bioscience Authority was established in 2004, the organization has committed $272 million to nearly 90 bioscience companies and other institutions.
The Venture Accelerator is an incubator with space available to growing bioscience companies.
Virginia-based Health Diagnostic Laboratory, Inc. will acquire and operate Oncimmune’s Desoto, Kansas lab and become the exclusive licensed U.S. provider of EarlyCDT- Lung, world’s first autoantibody test for early detection of lung cancer.
“KBA was an early investor in Oncimmune USA in 2006, investing $2 million in a convertible note to help the company establish its CLIA lab operation in Desoto, KS. We are delighted at this outcome and look forward to the continued success of the EarlyCDT-Lung test,” said Keith Harrington, KBA Director of Commercialization.
“Oncimmune’s subsidiary in the U.S. has been building sales and awareness of the EarlyCDT-Lung test on a steady basis for the past few years,” said Geoffrey Hamilton-Fairley, Executive Chairman of Oncimmune Ltd. “By licensing our first test to HDL, we have secured access to a distribution channel that will deliver greater volume more quickly and at the same time provide sufficient revenues so that the company can accelerate the launch of our other early cancer detection tests.”
Lung cancer is the leading cause of cancer deaths among men and women in the U.S., taking the lives of more people each year than colon, breast, prostate, and pancreatic cancers combined. Lung cancer claims more than three times as many men as prostate cancer and nearly twice as many women as breast cancer. The American Cancer Society predicts that in 2013 there will be approximately 228,000 new cases of lung cancer diagnosed and nearly 160,000 lung cancer associated deaths
Oncimmune USA’s 25 employees will join the 740-employee HDL, Inc. and will remain in the Desoto location as of the closing date for the transaction.
Silvergate Pharmaceuticals Inc. recently announced that the United States Food and Drug Administration (FDA) approved Epaned™ (enalapril maleate Powder for Oral Solution) to treat hypertension (high blood pressure) in people one month and older. Enalapril is one of the most commonly prescribed medicines in the United States to treat high blood pressure.
Silvergate has an office in the Venture Accelerator at the Kansas Bioscience Park. In addition, the company received a Proof of Concept Investment from the KBA in 2010 to fund the pre-IND meeting with the FDA. Silvergate Pharmaceuticals is dedicated to filling the unmet needs of children, developing innovative medications that will help improve the quality of care and outcomes for pediatric patients.
If you are a bioscience researcher, entrepreneur or industry leader, the Kansas Bioscience Park in Olathe, Kansas is your destination for innovation and growth. Kansas is investing in the success of researchers and businesses addressing national bioscience challenges—and the Kansas Bioscience Park is your portal to it all. Well positioned on prime land in one of the most economically vibrant and growing communities in the nation, this unique research and office park will surround you with a powerful mix of deep academic research resources, and tremendous industry strength.
The Kansas Bioscience Park is in the heart of the Kansas City Animal Health Corridor, which is home to one-third of the total sales in the $19 billion animal health market, and in one of the nation’s top concentrations of contract research organizations, BioResearch Central. The park is already home to the Kansas State University Olathe Campus, the Kansas Bioscience Authority at the Venture Accelerator, and the International Animal Health and Food Safety Institute.
The Kansas Bioscience Authority and Cassidy Turley have partnered with Hoefer Wysocki Architects to build a vision for the park and create a campus-like setting that will nurture growing businesses. Best of all, the KBA is offering free land to qualifying bioscience companies. For more information, go to www.kansasbiopark.com.